留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝细胞癌患者血清胸腺素β4水平

邢晶 韩涛 朱争艳 刘莹 刘华 郭震 马晓燕 裴彦祯

邢晶, 韩涛, 朱争艳, 刘莹, 刘华, 郭震, 马晓燕, 裴彦祯. 肝细胞癌患者血清胸腺素β4水平[J]. 临床肝胆病杂志, 2011, 27(4): 387-390.
引用本文: 邢晶, 韩涛, 朱争艳, 刘莹, 刘华, 郭震, 马晓燕, 裴彦祯. 肝细胞癌患者血清胸腺素β4水平[J]. 临床肝胆病杂志, 2011, 27(4): 387-390.
Xing Jing, Han Tao, Zhu ZhengYan, Liu Ying, Liu Hua, Guo Zhen, Ma XiaoYan, Pei YanZhen. Serum thymosin β4 level in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2011, 27(4): 387-390.
Citation: Xing Jing, Han Tao, Zhu ZhengYan, Liu Ying, Liu Hua, Guo Zhen, Ma XiaoYan, Pei YanZhen. Serum thymosin β4 level in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2011, 27(4): 387-390.

肝细胞癌患者血清胸腺素β4水平

基金项目: 国家重点基础研究发展规划基金资助项目(973计划)(2007CB512801); 国家“十一五”科技重大专项(2008ZX10002-005); 天津市卫生局重点攻关资助项目(07KG9);
详细信息
  • 中图分类号: R735.7

Serum thymosin β4 level in patients with hepatocellular carcinoma

  • 摘要: 目的检测肝细胞癌(HCC)患者血清胸腺素β4(Tβ4)水平及其影响因素。方法采用ELISA方法检测80例HCC患者血清Tβ4水平,并与40例健康人及30例肝硬化患者比较。同时比较不同肿瘤情况及肝功能对HCC组患者血清Tβ4浓度的影响。结果 HCC患者及肝硬化患者血清Tβ4水平均低于健康人,差异有统计学意义(χ2=81.228,P<0.001)。按照BCLC分期或CLIP分期将HCC患者分别分为4个或6个亚组,血清Tβ4浓度差异均有统计学意义(χ2=8.669~13.675,P<0.034)。HCC患者中有肝内转移组血清Tβ4浓度高于无肝内转移组,差异有统计学意义(Z=2.264,P=0.024);有门脉瘤栓组血清Tβ4浓度高于无门脉瘤栓组,差异有统计学意义(Z=2.574,P=0.010)。无肝内转移而且无远处转移的HCC患者按照肝功能Child-Pugh评分分为A、B、C级3组,血清Tβ4浓度差异有统计学意义(χ2=6.467,P=0.039)。结论肝细胞癌患者血清Tβ4浓度低于健康人,且肝功能越差,血清Tβ4浓度越低。而发生肝内转移或门脉瘤栓的患者血清Tβ4浓度高于未发...
  • [1]Low TL, Goldstein AL.Chemical characterization of thymosinbeta 4[J].J Biol Chem, 1982, 257 (2) :1000-1006.
    [2]Xu GJ, Hannappel E.Determination of thymosin beta 4 byperitoneal macrophages and adherent spleen cells[J].ProcNatl Acad Sci, 1982, 79 (13) :4006-4009.
    [3]Han T, Liu Y, Liu H, et al.Serum thymosinβ4 level inpatient with hepatitis B virus-related liver failure[J].World JGastroenterol, 2010, 16 (5) :625-630.
    [4]Bruix J, Sherman M.Management of hepatocellularcarcinoma[J].Hepatology, 2005, 42 (5) :1208-1236.
    [5]Llovet JM, Bru C, Bruix J.Prognosis of hepatocellularcarcinoma:the BCLC staging classification[J].Semin LiverDis, 1999, 19 (3) :329-338.
    [6]Llovet JM, Burroughs A, Bruix J.Hepatocellular carcinoma[J].Lancet, 2003, 362 (9399) :1907-1917.
    [7]The Cancer of the Liver Italian Program (CLIP) investigators.Prospective validation of the CLIP score:a new prognosticsystem for patients with cirrhosis and hepatocellularcarcinoma[J].Hepatology, 2000, 31 (4) :840-845.
    [8]Carlier MF, Didry D, Erk I, et al.Tbeta 4 is not a simple G-actinsequestering protein and interacts with F-actin at highconcentration[J].J Biol Chem, 1996, 271 (16) :9231-9239.
    [9]Philp D, Badamchian M, Scheremeta B, et al.Thymosin beta 4and a synthetic peptide containing its actin-binding domainpromote dermal wound repaire in db/db diabetic mice and inaged mice[J].Wound Repair Regen, 2003, 11 (1) :19-24.
    [10]Bock-Marqutte I, Saxena A, White MD, et al.Thymosin beta4 activates integrin-linked kinase and promotes cardiaccell migration, survival and cardiac repair[J].Nature, 2004, 432 (7016) :466-472.
    [11]Sosne G, Qiu P, Christopherson PL, et al.Thymosin beta4suppression of corneal NFκB:a potential anti-inflammatorypathway[J].Exp Eye Res, 2007, 84 (4) :663-669.
    [12]Cha HJ, Jeong MJ, Kleinman HK.Role of thymosinβ4 intumor metastasis and angiogenesis[J].J Natl Cancer Inst, 2003, 95 (22) :1674-1680.
    [13]Mai I, Kazuhiro I, Shigeyuki U, et al.Overexpression of thymosinβ4 increases pseudopodia formation in LNCaP prostatecancer cells[J].Biol Pharm Bull, 2009, 32 (6) :1101-1104.
    [14]Wang WS, Chen PM, Hsiao HL, et al.Overexpression ofthe thymosin beta 4 gene is associated with malignantprogression of SW480 colon cancer cells[J].Oncogene, 2003, 22 (21) :3297-3306.
    [15]Barnaeva E, Nadezhda A, Hannappel E, et al.Thymosin beta4upregulates the expression of hepatocyte growth factor anddownregulate the expression of PDGF-beta receptor in humanhepatic stellate cells[J].Ann N Y Acad Sci, 2007, 1112:154-160.
    [16]Hsiao HL, Wang WS, Chen PM, et al.Overexpression of thymosinbeta-4 renders SW480 colon carcinoma cells more resistant toapoptosis triggered by FasL and two topoisomeraseⅡinhibitorsvia downregulating Fas and upregulating Survivin expression, respectively[J].Carcinogenesis, 2006, 27 (5) :936-944.
  • 加载中
计量
  • 文章访问数:  3959
  • HTML全文浏览量:  3
  • PDF下载量:  885
  • 被引次数: 0
出版历程
  • 刊出日期:  2011-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回